Pancreatic cancer could be treated with a Parkinson's drug
The new research suggests that carbidopa, which is a drug approved by the Food and Drug Administration (FDA) and widely used to treat Parkinson's disease, has significant anti-cancer properties.
Carbidopa is typically used in conjunction with levodopa (L-Dopa) to treat Parkinson's disease. And previous studies have shown that patients with Parkinson's tend to have a lower incidence of cancer.
In older research, scientists investigated whether or not it was the drug L-Dopa that yielded the anti-cancer effect, but they did not find any significant results.
So now, a team led by Dr. Yangzom Bhutia - from the Texas Tech University Health Sciences Center (TTUHSC) in Lubbock - hypothesized that carbidopa alone could have anti-cancer properties.
Commenting on the motivation for the research, Dr. Bhutia says, "Interestingly, no one has previously suspected carbidopa as a potential player in this phenomenon."
"Carbidopa is never used by itself as a drug for any disease," she adds. "But [...] we believe that the reduced incidence of most cancers in Parkinson's disease patients is due to carbidopa."
The first author of the study is Jiro Ogura, of the Department of Cell Biology and Biochemistry at TTUHSC, and the findings were published in the Biochemical Journal.
Article originally published in Medical News Today, www.medicalnewstoday.com.
To read full article, please visit https://www.medicalnewstoday.com/articles/319578.php.
As spring approaches, some people’s thoughts turn to gardening. Whether it’s a flower garden they desire or a vegetable garden want to have, they begin planning what they’ll plant and what they need to do to ensure a successful garden.
A “growth mindset” accepts that our intelligence and talents can develop over time, and a person with that mindset understands that intelligence and talents can improve through effort and learning.
Abstaining from drug abuse and an early diagnosis of familial hypercholesterolemia (high cholesterol) can help prevent heart disease.
TTUHSC’s Castro-Quirino Named to 2023-24 Fellows of HACU’s Leadership Academy/La Academia de Liderazgo
HACU announced Sonya Castro-Quirino, D.Bioethics, TTUHSC vice president of Office of Institutional Compliance, as one of the 50 fellows of HACU’s Leadership Academy/La Academia de Liderazgo.
Ronald L. Cook, DO, MBA, of Lubbock, Texas, was named the 2023 Texas Family Physician of the Year during TAFP’s Annual Session and Primary Care Summit in Grapevine on Nov. 11.
Ninh (Irene) La-Beck, Pharm.D., with the TTUHSC Jerry H. Hodge School of Pharmacy, received a five-year, $2.49 million grant to investigate how nanoparticles interact with the immune system and cancer.